Hepatic hemangiosarcoma is a malignant mesenchymal tissue tumor of the liver, and hepatocellular carcinoma is a cancer of the liver cells, both of which are very serious. Hepatic hemangiosarcoma is clinically a relatively rare type of malignant tumor that originates from vascular epithelial tissue. The tumor is highly malignant, with rapid disease progression, high surgical risk and poor prognosis. Most patients are found in advanced stage with low cure rate. Most of the untreated patients die within 6 to 12 months, and the cause of death is usually liver failure or intra-abdominal hemorrhage. Hepatocellular carcinoma generally refers to primary hepatocellular carcinoma, which is a malignant tumor originating from hepatocytes or intrahepatic bile duct epithelial cells and has a poor prognosis. Primary hepatocellular carcinoma is highly malignant and the tumor grows rapidly, and untreated patients usually survive for only 3 to 6 months. If diagnosed with hepatic hemangiosarcoma or hepatocellular carcinoma, it is recommended to receive timely treatment in regular hospitals to avoid delay.